Newsroom

Sight Sciences OMNI® Surgical System to Be Featured in Multiple Presentations at the 2022 European Society of Cataract and Refractive Surgery Annual Meeting

Compendium of clinical presentations includes studies with up to 3.5 years of patient follow-up and over 400 eyes treated in 31 centers in both combination cataract and standalone use   MENLO PARK, Calif., Sept. 16, 2022 (GLOBE NEWSWIRE) — Sight Sciences, Inc. announced today that its OMNI Surgical System will be featured in seven clinical […]

read more +
Sight Sciences Announces Completion of Enrollment in SAHARA, a Randomized Clinical Trial of the TearCare® System vs Restasis®

310-patient RCT designed to evaluate the superiority of TearCare® (device) vs Restasis® (drug) in patients with chronic dry eye disease is now fully enrolled 6-Month efficacy results expected by Summer 2023

read more +
Sight Sciences to Present at the Upcoming Morgan Stanley Global Healthcare Conference

MENLO PARK, Calif., Sept. 02, 2022 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT) an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, today announced plans to participate in the upcoming Morgan Stanley Global Healthcare Conference in New York, NY. Sight Sciences’ management is scheduled to participate […]

read more +
Sight Sciences Introduces the SION™ Surgical Instrument – The First Bladeless Device Used in Goniotomy

Featuring bladeless technology, SION is designed to facilitate a smooth, gentle goniotomy procedure

read more +
Sight Sciences Announces Long-Term Safety and Effectiveness Data of Standalone Use of the OMNI® Surgical System in Patients with Open Angle Glaucoma

Three-year, standalone (not combined with cataract surgery) data shows the non-implantable minimally invasive glaucoma surgery effectively reduces intraocular pressure and reduces need for IOP-lowering medications in open-angle glaucoma patients

read more +
Sight Sciences Reports Second Quarter 2022 Financial Results

Sight Sciences Reports Second Quarter 2022 Financial Results   August 11, 2022 PDF Version   MENLO PARK, Calif., Aug. 11, 2022 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, today reported financial results for the second quarter ended […]

read more +
Sight Sciences to Report Second Quarter 2022 Financial Results on August 11, 2022

MENLO PARK, Calif., July 28, 2022 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, today announced it will report financial results for the second quarter ended June 30, 2022, after the market close on Thursday, August 11, 2022. […]

read more +
Sight Sciences Announces the Appointment of Tamara Fountain, M.D. to its Board of Directors

MENLO PARK, Calif., July 19, 2022 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, today announced the appointment of Tamara Fountain, M.D. to its Board of Directors, effective July 15, 2022. As part of her duties, Dr. Fountain […]

read more +